Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.

Eiger BioPharmaceuticals to Present at H.C. Wainwright Global Investment Conference

PALO ALTO, Calif, May 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:  EIGR ), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory,

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan

PALO ALTO, Calif. and OSAKA, Japan , May 10, 2022 /PRNewswire/ -- Eiger Biopharmaceuticals Inc. (" Eiger ", Nasdaq: EIGR) and AnGes Inc. (" AnGes ", TYO: 4563) today announced that the companies entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy ®

Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022 Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End Zokinvy ® (lonafarnib) CHMP Opinion Expected in Q2 2022 Phase 3 Avexitide Congenital Hyperinsulinism Program Initiation Planned by Year End Strong Cash